SMN1 and spinal muscular atrophy, type 1: AAV9 vector efficiency at penetrating the BBB has proven to be sufficient for the delivery of the SMN1 gene to lower motor neurons in spinal muscular atrophy type 1, leading to the FDA approval of the AAV9-SMN1 vector, Zolgensma [13].